Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
Nasdaq

Mainz Biomed Launches eAArly DETECT 2 Feasibility Study for Next Generation Colorectal Cancer Test

Mainz Biomed NV has launched the eAArly DETECT 2 feasibility study, aimed at validating previous results on advanced adenomas using a large population of approximately 2,000 average risk patients.
KHON2

Biomed Industries Presents Breakthrough Phase 2 Results of NA-931, an Oral Quadruple Agonist for Obesity , at ADA 2025

Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, a First-in-Class Oral Quadruple Agonist for the Treatment of Obesity , at ADA 2025 NA-931's Phase 2 results highlight its ...
Nasdaq

Mainz Biomed N.V. Announces Key Achievements and Corporate Update for First Half of 2025

Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, reported significant milestones for the first half of 2025, including the launch of the eAArly DETECT 2 US ...